Public Employees Retirement Association Of Colorado Cerevel Therapeutics Holdings, Inc. Transaction History

Public Employees Retirement Association Of Colorado

$25.2 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$38.96 - $42.75 $23,999 - $26,334	-616 Reduced 6.84%	8,389 $343,000
Q1 2024 May 15, 2024	SELL	$40.88 - $43.27 $79,716 - $84,376	-1,950 Reduced 17.8%	9,005 $381,000
Q4 2023 Feb 13, 2024	SELL	$20.27 - $42.44 $6,466 - $13,538	-319 Reduced 2.83%	10,955 $464,000
Q3 2023 Nov 14, 2023	BUY	$20.26 - $31.91 $183,575 - $289,136	9,061 Added 409.44%	11,274 $246,000
Q3 2023 Nov 14, 2023	SELL	$20.26 - $31.91 $229,829 - $361,987	-11,344 Reduced 83.68%	2,213 $133,000
Q2 2023 Aug 09, 2023	SELL	$23.9 - $35.38 $3,728 - $5,519	-156 Reduced 1.14%	13,557 $431,000
Q2 2022 Aug 15, 2022	BUY	$20.62 - $37.15 $282,762 - $509,437	13,713 New	13,713 $363,000

Others Institutions Holding CERE

# of Institutions

Shares Held

5.01M

Call Options Held

3.3K

Put Options Held

View Full List

About Cerevel Therapeutics Holdings, Inc.

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

More about CERE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Public Employees Retirement Association Of Colorado, based on Form 13F filings with the SEC.

News

Stay updated on Public Employees Retirement Association Of Colorado with notifications on news.

Account